
    
      Patients must be on stable antiretroviral treatment for at least 6 weeks prior to study entry
      and will then be stratified depending on whether their regimen contains zidovudine (ZDV).
      Each stratum will be randomized separately to receive 1592U89 or placebo for 12 weeks. For
      the subsequent 40 weeks, open-label 1592U89 will be offered.
    
  